- Home
- CHRS vs SRBK Comparison
CHRS vs SRBK Comparison
Compare CHRS & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SRBK
- Stock Information
- Founded
- CHRS 2010
- SRBK 1887
- Country
- CHRS United States
- SRBK United States
- Employees
- CHRS N/A
- SRBK N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SRBK
- Sector
- CHRS Health Care
- SRBK
- Exchange
- CHRS Nasdaq
- SRBK Nasdaq
- Market Cap
- CHRS 100.9M
- SRBK 95.0M
- IPO Year
- CHRS 2014
- SRBK N/A
- Fundamental
- Price
- CHRS $1.10
- SRBK $10.99
- Analyst Decision
- CHRS Strong Buy
- SRBK
- Analyst Count
- CHRS 4
- SRBK 0
- Target Price
- CHRS $6.13
- SRBK N/A
- AVG Volume (30 Days)
- CHRS 3.1M
- SRBK 28.8K
- Earning Date
- CHRS 11-06-2024
- SRBK 01-01-0001
- Dividend Yield
- CHRS N/A
- SRBK N/A
- EPS Growth
- CHRS N/A
- SRBK N/A
- EPS
- CHRS N/A
- SRBK 0.11
- Revenue
- CHRS $304,340,000.00
- SRBK $30,867,000.00
- Revenue This Year
- CHRS $3.33
- SRBK N/A
- Revenue Next Year
- CHRS $16.77
- SRBK N/A
- P/E Ratio
- CHRS N/A
- SRBK $95.14
- Revenue Growth
- CHRS 44.19
- SRBK 164.18
- 52 Week Low
- CHRS $0.66
- SRBK $8.94
- 52 Week High
- CHRS $3.70
- SRBK $11.28
- Technical
- Relative Strength Index (RSI)
- CHRS 69.14
- SRBK 49.07
- Support Level
- CHRS $0.70
- SRBK $10.75
- Resistance Level
- CHRS $0.89
- SRBK $11.11
- Average True Range (ATR)
- CHRS 0.10
- SRBK 0.16
- MACD
- CHRS 0.04
- SRBK -0.02
- Stochastic Oscillator
- CHRS 93.70
- SRBK 44.72
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.